MMR Vaccine and SSPE Risk in Immunocompromised Patients

Understanding SSPE and Its Relationship to Measles

SSPE develops from wild-type measles infection, typically occurring 7-10 years after natural measles disease, according to the Centers for Disease Control and Prevention 1
No documented cases exist linking MMR vaccine virus to SSPE in any population, immunocompromised or otherwise, as stated by the World Health Organization 1, 2

The American Academy of Pediatrics recommends that MMR should not be administered to severely immunocompromised patients due to the risk of vaccine-associated measles infection, which has been linked to deaths, as reported by the Centers for Disease Control and Prevention 1, 2
Enhanced replication of vaccine viruses occurs in severely immunocompromised persons, leading to potential disseminated vaccine-strain measles infection, according to the Infectious Diseases Society of America 1, 2
Case reports have documented vaccine-associated measles deaths in severely immunocompromised individuals, confirming that inadequate immune surveillance allows problematic vaccine virus replication, as stated by the Centers for Disease Control and Prevention 1, 2

The Centers for Disease Control and Prevention defines severe immunocompromise as including congenital immunodeficiency disorders, HIV infection with severe immunosuppression, active hematologic or generalized malignancy, current therapy with alkylating agents, antimetabolites, or radiation, and high-dose corticosteroids, with a strength of evidence level of high 1, 3, 4, 5
High-dose corticosteroids are defined as ≥2 mg/kg/day or ≥20 mg/day prednisone equivalent for ≥14 days, according to the National Institutes of Health 1, 3

The American Academy of Pediatrics recommends that HIV-infected patients who are NOT severely immunosuppressed should receive MMR, with a strength of evidence level of moderate 3
Asymptomatic HIV-infected persons without severe immunosuppression are recommended to receive MMR, according to the Centers for Disease Control and Prevention 1, 5
Low-dose or short-term corticosteroids do not contraindicate MMR, as stated by the Infectious Diseases Society of America 1

The Centers for Disease Control and Prevention recommends administering MMR ≥4 weeks before starting immunosuppressive therapy when possible, with a strength of evidence level of high 3
Wait ≥3 months after discontinuation of chemotherapy or high-dose corticosteroids before giving MMR, according to the National Institutes of Health 3
Patients with leukemia in remission may receive MMR after 3 months off chemotherapy, as stated by the American Cancer Society 1, 5

The Infectious Diseases Society of America recommends that all household contacts and healthcare workers should receive MMR vaccine to provide herd immunity, with a strength of evidence level of high 4, 6, 3
Transmission of MMR vaccine strains from vaccinated contacts is extraordinarily rare, according to the Centers for Disease Control and Prevention 4, 6